Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij,Thomas G Martin,Nitya Nathwani,Mark A Fiala,Feng Gao,Abhinav Deol,Francis K Buadi,Jonathan L Kaufman,Craig C Hofmeister,Tara K Gregory,Jesus G Berdeja,Ajai Chari,Ashley E Rosko

doi:10.1182/blood-2019-130644

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, Thomas G Martin + Show 11 more

Open Access

https://doi.org/10.1182/blood-2019-130644

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 11

Affiliation: Washington University in St. Louis, University of California, San Francisco, City of Hope, Wayne State University, Mayo Clinic, Emory University, Colorado Blood Cancer Institute, Mount Sinai Hospital, The Ohio State University

#Advisory Committees #Lenalidomide Maintenance + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Full Text